ESH MM 2018 | MRD as a response assessment in elderly multiple myeloma
Alessandra Larocca
• 5 Oct 2018
Measurable residual disease (MRD) is gaining traction as a tool for response assessment, prognosis and clinical decision making in the field of hem-onc; could it be particularly useful in the management of elderly multiple myeloma? We spoke to Alessandra Larocca, MD, PhD, of the University Hospital Città della Salute e della Scienza, Torino, Italy, on just that at the European School of Haematology (ESH) International Conference on Multiple Myeloma 2018, held in Mandelieu, France.
